Particle.news
Health ❯ Healthcare ❯ Regulatory Affairs
Drug Approval Process Medical Devices Diagnostic Tests Clinical Trials Clinical Guidelines Drug Applications Drug Review Process Accelerated Approval Drug Development Drug Safety New Drug Application Phase 3 Trials Biologics License Application Priority Review Medical Device Approval Vaccine Conditions Medical Innovations Vaccine Approval Process Software as a Medical Device Surrogate Endpoints Orphan Drug Designation Medical Device Clearance Breakthrough Therapy Designation Drug Launches Clinical Study Results Product Candidates Drug Efficacy Drug Licensing Cancer Treatments Supplemental Biologics License Application Drug Approval Timelines Gene Therapy Approval Drug Submissions Fast Track Designation NDA Submission At-home Administration Alzheimer's Disease New Treatments Medicare Coverage Clinical Research New Drug Applications Biosimilars Vaccine Authorization Ozempic and Wegovy Drug Designation BLA Submission Prescription Medications Clinical Testing Drug Monitoring Gilead Sciences Drug Sales
The once-daily medicine targets neurokinin signaling to offer an option for women who cannot use estrogen therapy.
